Neuroscience Outcomes and Research 2020 - Vol 4
Volume 4 highlighted the work that Jefferson Health is doing in the arena of precision medicine for Amyotrophic Lateral Sclerosis (ALS). This included the work in their four research laboratories, as well as ongoing research into C9orf72 repeat expansions, nucleotide repeat expansions, and blood-brain barrier driven pharmacoresistance in ALS.
The journal also reported on the clinical research and trials at the division including their involvement in a new ALS initiative. Jefferson Health will be one of 54 centers nationally selected as a site for an upcoming Platform trial.